Navigation Links
Stereotactic Radiotherapy Stops Lung Cancer From Growing in Frail Patients
Date:11/2/2009

CHICAGO, Nov. 2 /PRNewswire-USNewswire/ -- Stereotactic body radiation therapy (SBRT) stopped the growth of cancer at its original site in the lung for three years among nearly 98 percent of patients with early non-small cell lung cancer (NSCLC) who are unable to have the cancer surgically removed, according to an updated three-year study presented November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

The study also shows that more than half (56 percent) of these patients lived for three years after diagnosis, while 48 percent survived for three years after cancer treatment with no sign of the disease returning. Researchers also found that despite the high potency of treatment, less than 20 percent of these extremely frail patients experienced a serious decline in their health status. This finding was better than researchers expected and is similar to the risks for healthier patients to undergo radical surgery.

"The results of the RTOG 0236 study confirms that SBRT should now be considered a standard treatment in early-stage lung cancer patients with co-existing serious medical problems, such as emphysema, heart disease and stroke," Robert D. Timmerman, M.D., lead author of the Radiation Therapy Oncology Group (RTOG) study and a radiation oncologist at the University of Texas Southwestern Medical Center in Dallas said. "It also begs the question of whether SBRT should be considered in healthier patients with lung cancer who are treated with surgery."

Stereotactic body radiation therapy is a specialized type of external beam radiation therapy that pinpoints high doses of radiation directly on the cancer in a shorter amount of time than traditional treatments. Cancer centers often call the treatments by the brand names of the manufacturers, including Axesse, CyberKnife, Gamma Knife, Novalis, Primatom, Synergy, X-Knife, TomoTherapy and Trilogy. Treatment in the study was delivered in 1½ to 2 weeks, instead of a typical period of 6 to 8 weeks.

For the past century, the standard treatment for early-stage NSCLC has been radical surgery that has involved removing a lobe or even the entire lung on the affected side. This surgery can be difficult for many patients as other medical conditions can hinder their recovery. The phase II trial took place from May 2004 to October 2006 and involved 55 patients at eight RTOG institutions in the U.S. and Canada. They received SBRT with a dose of 54 Gy in three fractions. The medium follow-up after treatment was 34 months.

The study was supported by grants from the National Cancer Institute and Advanced Technology Consortium.

For more information on radiation therapy for lung cancer and stereotactic radiation therapy, visit www.rtanswers.org.

The abstract, "Analysis of RTOG 0236: Stereotactic Body Radiation Therapy for Medically Inoperable Early-stage Lung Cancer Patients," was presented at a scientific session at 11:10 a.m. on Monday, November 2, 2009. To speak to the lead author of the study, Robert D. Timmerman, M.D., please call Beth Bukata or Nicole Napoli November 1-4, 2009, in the ASTRO Press Room at McCormick Place West at 312-791-7005 or 312-791-7006. You may also e-mail them at bethb@astro.org or nicolen@astro.org.

SOURCE American Society for Radiation Oncology


'/>"/>
SOURCE American Society for Radiation Oncology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotactic Radiosurgery As Effective in Eliminating Parkinsons Disease Tremors As Other Treatments, But Less Invasive
2. Stereotactic radiosurgery preferred method of treating cancer patients with brain metastases
3. Lower-dose fractionated stereotactic radiotherapy results in better hearing preservation
4. Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures : Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers
5. BrainLAB Announces 510(k) FDA Clearance of Monte Carlo Dose Engine for Stereotactic Radiosurgery and Radiation Therapy
6. IAME Goes Live With New Stereotactic Breast Program
7. Identification of highly radiosensitive patients may lead to side effect-free radiotherapy
8. Guatemala Treatment Center Becomes First in Latin America to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments
9. Premion First in Australia to Treat Cancer Patients with RapidArc(R) Radiotherapy Technology from Varian Medical Systems
10. Fatigue related to radiotherapy may be caused by inflammation
11. Londons Barts Hospital Selects Varian Equipment to Offer Advanced Radiotherapy to More Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 05, 2016 , ... Chronic stress can have a silent, yet dangerous, impact ... immune system and increase inflammation, both of which raise the risk of heart attack ... disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to other ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... honored finalists and winners Tuesday evening, May 3, at the 2016 ISE® Central ... , Scott Pettigrew, Vice President and Chief Security Officer of HMS, was selected ...
(Date:5/5/2016)... , ... May 05, 2016 , ... If you don’t ... marks on your skin, you may want to consider a treatment that some have ... Advanced Dermatology P.C. , Microneedling, also known as skin needling, is a ...
(Date:5/5/2016)... Austin, TX (PRWEB) , ... May 05, 2016 , ... ... existence to offer the breakthrough technology of the new PiQo4™ laser, the first 4-wavelenth ... treating more tattoo inks than any other picosecond laser on the market. Jeremy ...
(Date:5/5/2016)... ... 05, 2016 , ... Liposuction specialist Marcia V. Byrd, MD spoke last month ... the Marriot St. Louis Airport Hotel. This year’s conference was titled “Living with Lipedema ... her unique specialization in treating Lipedema. Dr. Byrd is considered one of the leading ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... CITY, Mo. , May 3, 2016 /PRNewswire/ ... Kansas Medical Center,s Institute for Advancing Medical Innovation ... and commercialize new drugs, diagnostics and medical devices. ... provides BioNovus Innovations with rights to license, develop ... "This partnership represents ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, an ... rheumatic fever, which damaged his heart. He continued enjoying ... by June 2013, Shepherd,s heart was giving out and ... On June 20, 2013, the Mesa, Arizona ... Heart (TAH-t). Like a heart transplant, the SynCardia TAH-t ...
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology: